Corpus overview


Overview

MeSH Disease

Human Phenotype

Melanoma (2)


Transmission

Seroprevalence

antibody (1)

    displaying 1 - 2 records in total 2
    records per page




    Unemployment and health-related quality of life in melanoma HP melanoma MESHD patients during the COVID-19 pandemic: A web-based cross-sectional study

    Authors: Yeye Guo; Minxue Shen; Xu Zhang; Yi Xiao; Shuang Zhao; Mingzhu Yin; Wenbo Bu; Yan Wang; Xiang Chen; Juan Su

    doi:10.21203/rs.3.rs-37039/v1 Date: 2020-06-19 Source: ResearchSquare

    Background The outbreak of coronavirus disease-2019 (COVID-19) ineluctably caused social distancing and unemployment, which may bring additional health risks for patients with cancer MESHD. To investigate the association of the pandemic-related impacts with the health-related quality of life (HRQoL) among patients with melanoma HP melanoma MESHD during the COVID-19 pandemic, we conducted a cross-sectional study among Chinese patients with melanoma HP melanoma MESHD.Methods A self-administered online questionnaire was distributed to melanoma HP melanoma MESHD patients through social media. Demographic and clinical data, and pandemic-related impacts (unemployment and income loss) were collected. HRQoL was determined by the Functional Assessment of Cancer Therapy-General (FACT-G) and its disease-specific module (the melanoma HP melanoma MESHD subscale, MS MESHD).Results A total of 70 patients with melanoma HP melanoma MESHD completed the study. The mean age TRANS of the patients was 55.2 ± 14.8 years, 45.7% (32/70) were male TRANS, and 21.4% (15/70) were unemployed since the epidemic. Unemployment of the patients and their family members TRANS and income loss MESHD were significantly associated with a lower FACT-G score, while the MS score was associated with the unemployment of the patients’ family members TRANS.Conclusions Our findings suggested that unemployment is associated with impaired HRQoL in melanoma MESHD melanoma HP patients during the COVID-19 epidemic.

    Cancer MESHD immunotherapy does not increase the risk of death by COVID-19 in melanoma HP melanoma MESHD patients

    Authors: Maria Gonzalez-Cao; Monica Antonazas-Basa; Teresa Puertolas; Eva Munoz-Couselo; Jose Luis Manzano; Cristina Carrera; Ivan Marquez-Rodas; Pilar Lopez-Criado; Juan Francisco Rodriguez-Moreno; Almudena Garcia-Castano; Juan Martin-Liberal; Pedro Rodriguez-Jimenez; Susana Puig; Pablo Cerezuela; Marta Feito-Rodriguez; Belen Rubio-Viqueira; Guillermo Crespo; Pablo Luna-Fra; Cristina Aguayo; Pablo Ayala de Miguel; Rosa Feltes; Lara Valles; Ana Drozdowskyj; Ainara Soria; Cayetana Maldonado; Luis Fernandez-Morales; Rafael Rosell; Mariano Provencio; Alfonso Berrocal

    doi:10.1101/2020.05.19.20106971 Date: 2020-05-21 Source: medRxiv

    Background: Covid-19 pandemic by the new coronavirus SARS-Cov-2 has produced devastating effects on the health care system, affecting also cancer MESHD patient care. Data about COVID-19 infection in cancer MESHD patients are scarce, and they point out a higher risk of complications due to the viral infection MESHD in this population. Moreover, cancer MESHD treatments could increase viral complications, specially those treatments based on the use of immunotherapy with checkpoints antibodies SERO. There are no clinical data about the safety of immune check point antibodies SERO in cancer MESHD patients when they become infected by SARS-CoV-2. As checkpoint inhibitors, mainly anti PD-1 and anti CTLA-4 antibodies SERO, are an effective treatment for most melanoma HP melanoma MESHD patients, avoiding their use during the pandemic could lead to a decrease in the chances of curing melanoma HP melanoma MESHD. Methods: In Spain we have started a national registry of melanoma HP melanoma MESHD patients infected by SARS-Cov-2 since April 1st, 2020. A retrospective analysis of patients included in the Spanish registery has been performed weekly since the activation of the study. Interim analysis shows unexpected findings about cancer MESHD treatment safety in SARS-Cov-2 infected melanoma MESHD melanoma HP patients, so a rapid communication to the scientific community is mandatory Results: Fifty patients have been included as of May 17th, 2020. Median age TRANS is 69 years (range 6 to 94 years), 27 (54%) patients are males TRANS and 36 (70%) patients have stage IV melanoma HP melanoma MESHD. Twenty-two (44%) patients were on active anticancer treatment with anti PD-1 antibodies SERO, 16 (32%) patients were on treatment with BRAF plus MEK inhibitors and 12 (24%) patients were not on active cancer treatment. COVID-19 episode has been resolved in 43 cases, including 30 (70%) patients cured, four (9%) patients that have died due to melanoma HP melanoma MESHD progression, and nine (21%) patients that have died from COVID-19. Mortality rates from COVID-19 according to melanoma HP melanoma MESHD treatment type were 16%, 15% and 36% for patients on immunotherapy, targeted drugs, and for those that were not undergoing active cancer MESHD treatment, respectively. Conclusion: These preliminary findings show that the risk of death MESHD in those patients undergoing treatment with anti PD-1 antibodies SERO does not exceed the global risk of death MESHD in this population. These results could be relevant in order to select melanoma HP melanoma MESHD therapy during the COVID-19 pandemic

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.